Tetradecanedioic acid
(Synonyms: 十四烷二酸) 目录号 : GC61325
Tetradecanedioic acid (Tetradecanedicarboxylate) is a C14 dicarboxylic acid.
Cas No.:821-38-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Tetradecanedioic acid (Tetradecanedicarboxylate) is a C14 dicarboxylic acid.
| Cas No. | 821-38-5 | SDF | |
| 别名 | 十四烷二酸 | ||
| Canonical SMILES | OC(=O)CCCCCCCCCCCCC(O)=O | ||
| 分子式 | C14H26O4 | 分子量 | 258.36 |
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.8706 mL | 19.3528 mL | 38.7057 mL |
| 5 mM | 0.7741 mL | 3.8706 mL | 7.7411 mL |
| 10 mM | 0.3871 mL | 1.9353 mL | 3.8706 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Metabolic engineering for the production of dicarboxylic acids and diamines
Metab Eng 2020 Mar;58:2-16.PMID:30905694DOI:10.1016/j.ymben.2019.03.005.
Microbial production of chemicals and materials from renewable carbon sources is becoming increasingly important to help establish sustainable chemical industry. In this paper, we review current status of metabolic engineering for the bio-based production of linear and saturated dicarboxylic acids and diamines, important platform chemicals used in various industrial applications, especially as monomers for polymer synthesis. Strategies for the bio-based production of various dicarboxylic acids having different carbon numbers including malonic acid (C3), succinic acid (C4), glutaric acid (C5), adipic acid (C6), pimelic acid (C7), suberic acid (C8), azelaic acid (C9), sebacic acid (C10), undecanedioic acid (C11), dodecanedioic acid (C12), brassylic acid (C13), Tetradecanedioic acid (C14), and pentadecanedioic acid (C15) are reviewed. Also, strategies for the bio-based production of diamines of different carbon numbers including 1,3-diaminopropane (C3), putrescine (1,4-diaminobutane; C4), cadaverine (1,5-diaminopentane; C5), 1,6-diaminohexane (C6), 1,8-diaminoctane (C8), 1,10-diaminodecane (C10), 1,12-diaminododecane (C12), and 1,14-diaminotetradecane (C14) are revisited. Finally, future challenges are discussed towards more efficient production and commercialization of bio-based dicarboxylic acids and diamines.
Enhancement of α,ω-Dicarboxylic Acid Production by the Expression of Xylose Reductase for Refactoring Redox Cofactor Regeneration
J Agric Food Chem 2018 Apr 4;66(13):3489-3497.PMID:29537267DOI:10.1021/acs.jafc.8b00376.
The production of α,ω-dicarboxylic acids (DCAs) by whole-cell biocatalysis is often limited by cofactor regeneration. Here, ω-oxidation pathway genes (monooxygenase, alcohol dehydrogenase, and aldehyde dehydrogenase) were coexpressed with a xylose reductase (XR) gene to regenerate cofactors in an engineered Escherichia coli strain that cometabolizes glucose and xylose. The resulting strain exhibited a 180% increase in DCA production compared with the control strain without XR, and produced xylitol in the presence of xylose. Expression of monooxygenase and XR without other ω-oxidation pathway genes resulted in an additional increase in Tetradecanedioic acid concentration and a substrate conversion of 95%, which was 198% higher than that associated with the control strain. The expression of XR helped the system to regenerate and balance the cofactors thereby achieving maximum substrate conversion efficiency. It could serve as an efficient platform for the industrial production of α,ω-DCAs.
[Degradation of fatty acid by syntrophic hydrocarbon-degrading consortium M82]
Wei Sheng Wu Xue Bao 2014 Nov 4;54(11):1369-77.PMID:25752144doi
Objective: Using molecular ecology methods, we screened non-hydrocarbon carbon sources suitable for growth of syntrophic hydrocarbon-degrading Syntrophus sp. Methods: The acclimated methanogenic hexadecane-degrading consortium M82 was subcultured with dodecanedioic acid, Tetradecanedioic acid, hexadecanoic acid, propionate and lactate. PCR-DGGE and qPCR were used to analyze the abundance and quantity of syntrophaceae using different carbon sources. The T-RFLP was applied to analyze archaeal community. Results: The consortium M82 could grow and produce methane using a variety of fatty acids that also resulted in the change in bacterial microbial community structure. Syntrophaceae bacterial stripe was obviously detected in the culture added additional dodecanedioic acid and Tetradecanedioic acid. Furthermore, the results show that the logarithmic abundance of Syntrophaceae was 7.4 and 7.6 in per milliliter culture in the two enrichment cultures respectively, which were 2 - 3 units higher than these in other cultures. The archaeal community structure was mainly composed of acetoclastic methanogens Methanosaeta and hydrogenotrophic methanogens Methanoculleus in all culture. Conclusion: Syntrophus sp. can use non-hydrocarbon carbon source (dodecanedioic acid and Tetradecanedioic acid) as substrate to grow, which provides valuable information to isolate syntrophic hydrocarbon bacteria, and reveal the molecular mechanism of syntrophic hydrocarbon degradation.
Identification of unknown impurity of azelaic acid in liposomal formulation assessed by HPLC-ELSD, GC-FID, and GC-MS
AAPS PharmSciTech 2014 Feb;15(1):111-20.PMID:24166667DOI:10.1208/s12249-013-0038-y.
The identification of new contaminants is critical in the development of new medicinal products. Many impurities, such as pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, decanedioic acid, undecanedioic acid, dodecanedioic acid, tridecanedioic acid, and Tetradecanedioic acid, have been identified in samples of azelaic acid. The aim of this study was to identify impurities observed during the stability tests of a new liposomal dosage form of azelaic acid that is composed of phosphatidylcholine and a mixture of ethyl alcohol and water, using high-performance liquid chromatography with evaporative light-scattering detector (HPLC-ELSD), gas chromatography-flame ionisation detection (GC-FID), and gas chromatography-mass spectrometry (GC-MS) methods. During the research and development of a new liposomal formulation of azelaic acid, we developed a method for determining the contamination of azelaic acid using HPLC-ELSD. During our analytical tests, we identified a previously unknown impurity of a liposomal preparation of azelaic acid that appeared in the liposomal formulation of azelaic acid during preliminary stability studies. The procedure led to the conclusion that the impurity was caused by the reaction of azelaic acid with one of the excipients that was applied in the product. The impurity was finally identified as an ethyl monoester of azelaic acid. The identification procedure of this compound was carried out in a series of experiments comparing the chromatograms that were obtained via the following chromatographic methods: HPLC-ELSD, GC-FID, and GC-MS. The final identification of the compound was carried out by GC with MS.
Discovery and Validation of Pyridoxic Acid and Homovanillic Acid as Novel Endogenous Plasma Biomarkers of Organic Anion Transporter (OAT) 1 and OAT3 in Cynomolgus Monkeys
Drug Metab Dispos 2018 Feb;46(2):178-188.PMID:29162614DOI:10.1124/dmd.117.077586.
Perturbation of organic anion transporter (OAT) 1- and OAT3-mediated transport can alter the exposure, efficacy, and safety of drugs. Although there have been reports of the endogenous biomarkers for OAT1/3, none of these have all of the characteristics required for a clinical useful biomarker. Cynomolgus monkeys were treated with intravenous probenecid (PROB) at a dose of 40 mg/kg in this study. As expected, PROB increased the area under the plasma concentration-time curve (AUC) of coadministered furosemide, a known substrate of OAT1 and OAT3, by 4.1-fold, consistent with the values reported in humans (3.1- to 3.7-fold). Of the 233 plasma metabolites analyzed using a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based metabolomics method, 29 metabolites, including pyridoxic acid (PDA) and homovanillic acid (HVA), were significantly increased after either 1 or 3 hours in plasma from the monkeys pretreated with PROB compared with the treated animals. The plasma of animals was then subjected to targeted LC-MS/MS analysis, which confirmed that the PDA and HVA AUCs increased by approximately 2- to 3-fold by PROB pretreatments. PROB also increased the plasma concentrations of hexadecanedioic acid (HDA) and Tetradecanedioic acid (TDA), although the increases were not statistically significant. Moreover, transporter profiling assessed using stable cell lines constitutively expressing transporters demonstrated that PDA and HVA are substrates for human OAT1, OAT3, OAT2 (HVA), and OAT4 (PDA), but not OCT2, MATE1, MATE2K, OATP1B1, OATP1B3, and sodium taurocholate cotransporting polypeptide. Collectively, these findings suggest that PDA and HVA might serve as blood-based endogenous probes of cynomolgus monkey OAT1 and OAT3, and investigation of PDA and HVA as circulating endogenous biomarkers of human OAT1 and OAT3 function is warranted.